English | 简体中文 | 繁體中文 | 한국어 | 日本語
Sunday, 14 February 2021, 01:00 HKT/SGT
Share:
    

Source: Cofttek Holding Limited
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors

LUOHE CITY, China, Feb 14, 2021 - (ACN Newswire) - Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, has recently drawn the attention of investors, following the U.S. introduction of the FDA drug ultramicronized Palmitoylethanolamide (PEA) for COVID-19 patients. Cofttek is China's largest manufacturer of ultramicronized Palmitoylethanolamide (PEA) raw materials. Following the U.S. news, orders at Cofttek have surged, and production capacity has been saturated.

Cofttek founder Dr. Zeng explained, "Following this FDA news, the share price of FSD Pharma (NASDAQ: HUGE), our main competitor in the USA, roared from $3 to $14 in a few days. As the largest PEA manufacturer in China, Cofttek has attracted similar attention from many investors in the industry."

About Palmitoylethanolamide (PEA): https://www.cofttek.com/product/544-31-0/

Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent, one that is also found in foods such as eggs and milk, no serious side effects or drug-drug interactions have been identified.

PEA is a naturally occurring fatty acid. It is similar to an endocannabinoid, which is one of a suite of molecules found in cannabis targeting CB2 receptors. CB2 receptors can modulate both inflammation and pain throughout the human body. COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm, which is not a virus killer. But Cofttek believes it can mitigate that immune response, which can be fatal.

About Cofttek

Cofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, in Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.

Media Contact:
Dr. Zeng, Cofttek Holding Limited
E: [email protected],T: 86 1390 2465871
Website: https://www.cofttek.com

Source: Cofttek Holding Limited


Topic: Press release summary
Source: Cofttek Holding Limited

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
MHI Thermal Systems Confirms Effectiveness of Air Purification Filtering Technology for Removal and Inactivation of SARS-CoV-2  
May 12, 2021 11:17 HKT/SGT
Collaboration with South Pole to Generate and Sell Carbon Credits from Carbon Removal Technologies  
May 12, 2021 11:02 HKT/SGT
Fujitsu Signs Strategic Collaboration Agreement with AWS to Accelerate Digital Transformation in the Mobility Industry  
May 12, 2021 09:51 HKT/SGT
NutryFarm Ventures Into Singapore's Durian Market with Established Singapore E-Commerce Company, Ebuy  
May 12, 2021 08:01 HKT/SGT
Duet Protocol closes first-round funding at US$3 million  
May 12, 2021 03:00 HKT/SGT
Mitsubishi Power Receives Turnkey Order for 50MW Woody Biomass-fired Power Generation Facility  
May 11, 2021 17:39 HKT/SGT
Finance, Technology and Off-taker Deployment Themes of Solar & Storage Finance Asia  
May 11, 2021 16:55 HKT/SGT
Nissin Foods Delivers Stable 2021 Q1 Financial Results   
May 11, 2021 13:11 HKT/SGT
Eisai's Statement of Commitment for Carbon Neutrality by 2040  
May 11, 2021 09:00 HKT/SGT
Trintech Releases 2021 Global Financial Close Benchmark Report  
May 11, 2021 00:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575